Global distribution and outcomes for Candida species causing invasive candidiasis: Results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 22, Issue 8, 2003, Pages 470-474

  Colombo, A L ^a   Perfect, J ^b   DiNubile, M ^c   Bartizal, K ^c   Motyl, M ^c   Hicks, P ^c   Lupinacci, R ^c   Sable, C ^c   Kartsonis, N ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; FUNGUS ISOLATION; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; CANDIDA; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FUNGEMIA; HUMANS; INCIDENCE; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PEPTIDES; PEPTIDES, CYCLIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0042410872     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-003-0973-8     Document Type: Article

References (47)

1. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M (2002) Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 40:3489-3492
2. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, Pfaller MA (2002) Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 40:1298-1302
3. Doczi I, Dosa E, Hajdu E, Nagy E (2002) Aetiology and antifungal susceptibility of yeast bloodstream infections in a Hungarian university hospital between 1996 and 2000. J Med Microbiol 51:677-681
4. Krcmery V, Laho L, Huttova M, Ondrusova A, Kralinsky K, Pevalova L, Dluhohicky S, Pisarcikova M, Hanzen J, Filka J, Sejnova D, Liskova A, Purgelova A, Szovenyova Z, Koren P (2002) Aetiology, antifungal susceptibility, risk factors and outcome in 201 fungaemic children: data from a 12-year prospective national study from Slovakia. J Med Microbiol 51:110-116
5. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A (2002) Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 45:141-145
6. Marriott D, Laxton M, Harkness J (2001) Candida dubliniensis candidemia in Australia. Emerg Infect Dis 7:479
7. Mathews MS, Samuel PR, Suresh M (2001) Emergence of Candida tropicalis as the major cause of fungaemia in India. Mycoses 44:278-280
8. McMullan R, McClurg R, Xu J, Moore J, Millar B, Crowe M, Hedderwick S (2002) Trends in the epidemiology of Candida bloodstream infections in Northern Ireland between January 1984 and December 2000. J Infect 45:25
9. Moosa MY, Sobel JD (2002) Non-albicans Candida infections in patients with hematologic malignancies. Semin Respir Infect 17:91-108
10. Richer H, Roux P, Des CC, Esnault Y, Andremont A (2002) Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 8:405-412
11. Slavin MA (2002) The epidemiology of candidaemia and mould infections in Australia. J Antimicrob Chemother 49 (Suppl 1):3-6
12. Wu S, Liao W, Guo N (2001) Epidemiological study of pathogenic fungi in China: 1986 and 1996. Chin Med J (Engl) 114:294-296
13. Alves SH, Milan EP, Branchini ML, Nishimura K, Fukushima K, Oliveira LO, Costa JM, Colombo AL (2001) First isolation of Candida dubliniensis in Rio Grande do Sul, Brazil. Diagn Microbiol Infect Dis 39:165-168
14. Fairchild KD, Tomkoria S, Sharp EC, Mena FV (2002) Neonatal Candida glabrata sepsis: clinical and laboratory features compared with other Candida species. Pediatr Infect Dis J 21:39-43
15. Hope W, Morton A, Eisen DP (2002) Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 50:56-65
16. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA (1998) International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 36:1886-1889
17. Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ (1999) International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 35:19-25
18. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ (2000) Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 44:747-751
19. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, Messer SA (2001) International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39:3254-3259
20. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, Hachem RY, Kontoyiannis DP, Raad II (2002) The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 112:380-385
21. Chryssanthou E (2001) Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method. J Clin Microbiol 39:4181-4183
22. Kovacicova G, Krupova Y, Lovaszova M, Roidova A, Trupl J, Liskova A, Hanzen J, Milosovic P, Lamosova M, Macekova L, Szovenyiova Z, Purgelova A, Obertik T, Bille J, Krcmery V (2000) Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fiuconazole and the outcome of fungemia? J Infect Chemother 6:216-221
23. Krcmery V, Barnes AJ (2002) Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 50:243-260
24. Leung AY, Chim CS, Ho PL, Cheng VC, Yuen KY, Lie AK, Au WY, Liang R, Kwong YL (2002) Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors. J Hosp Infect 50:316-319
25. Saiman L, Ludington E, Dawson JD, Patterson JE, Rangel-Frausto S, Wiblin RT, Blumberg HM, Pfaller M, Rinaldi M, Edwards JE, Wenzel RP, Jarvis W (2001) Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 20:1119-1124
26. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP (2002) Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35:627-630
27. Viscoli C, Girmenia C, Marinus A Viscoli C, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, De Pauw B, Meunier F (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28:1071-1079
28. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. New Engl J Med 347:2020-2029
29. Silva CL da, Santos RM dos, Colombo AL (2001) Cluster of Candida parapsilosis primary bloodstream infection in a neonatal intensive care unit. Braz J Infect Dis 5:32-36
30. Levy I, Rubin LG, Vasishtha S, Tucci V, Sood SK (1998) Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 26:1086-1088
31. Colombo AL, Nucci M, Salomao R, Branchini ML, Richtmann R, Derossi A, Wey SB (1999) High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 34:281-286
32. Lupetti A, Tavanti A, Davini P, Ghelardi E, Corsini V, Merusi I, Boldrini A, Campa M, Senesi S (2002) Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol 40:2363-2369
33. Nucci M, Anaissie E (2002) Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 34:591-599
34. Sypula WT, Kale-Pradhan PB (2002) Therapeutic dilemma of fluconazole prophylaxis in intensive care. Ann Pharmacother 36:155-159
35. Marr KA (2000) The changing spectrum of candidemia in oncology patients: therapeutic implications. Curr Opin Infect Dis 13:615-620
36. Kataoka S, Kashiwa M, Saku K, Handa N, Akiyama H (1995) Candidemia in non-neutropenic patients with an intravenous hyperalimentation catheter: good prognosis of Candida parapsilosis infection. Kansenshogaku Zasshi 69:969-974
37. Collin B, Clancy CJ, Nguyen MH (1999) Antifungal resistance in non-albicans Candida species. Drug Resist Updat 2:9-14
38. Edwards JE Jr, Bodey GP, Bowden RA, Buchner T, Pauw BE de, Filler SG, Ghannoum MA, Glauser M, Herbrecht R, Kauffman CA, Kohno S, Martino P, Meunier F, Mori T, Pfaller MA, Rex JH, Rogers TR, Rubin RH, Solomkin J, Viscoli C, Walsh TJ, White M (1997) International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 25:43-59
39. Kam LW, Lin JD (2002) Management of systemic candidal infections in the intensive care unit. Am J Health Syst Pharm 59:33-41
40. Rogers TR (2001) Optimal use of existing and new antifungal drugs. Curr Opin Crit Care 7:238-241
41. Singh N (2001) Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 7 (Suppl 2): 1-7
42. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ (2002) Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 4:25-30
43. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA (2002) Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46:1773-1780
44. Hoffman HL, Rathbun RC (2002) Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 11:409-429
45. Roilides E, Kadiltsoglou I, Zahides D, Bibashi E (1997) Invasive candidosis in pediatric patients. Clin Microbiol Infect 3:192-197
46. Groll AH, Walsh TJ (2001) Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 10:1545-1558
47. Marr KA (2002) Empirical antifungal therapy - new options, new tradeoffs. N Engl J Med 346:278-280